News

A new study published in the Journal of Electrocardiology this month by Washington University Physician Adam May shows that an automated tool for WCT differentiation can improve the accuracy of the physician interpreting ECGs.

Dr. Alan Zajarias and the team at the Valvular Heart Disease Center have been invited to join the Edwards Triscend 2 pivotal trial, testing the safety and effectiveness of the Evoque valve device in patients with tricuspid regurgitation. The Evoque tricuspid valve replacement system is designed to use an implant to replace the native tricuspid […]

An estimated 1,000,000 people in the U.S. have hypertrophic cardiomyopathy. Washington University interventional cardiologist Richard Bach, MD, FACC, and his team had exhausted non-invasive treatments for a patient suffering from HCM. Until, that is, Bach enrolled the man, who was in his 50s, in a clinical trial evaluating a drug called mavacamten.

It is my pleasure to announce that Dr. Nancy K. Sweitzer, Professor of Medicine, has joined Washington University School of Medicine as the Vice Chair of Clinical Research for the Department of Medicine and Director of Clinical Research for the Division of Cardiology. Dr. Sweitzer joins us from the University of Arizona in Tucson, where she had been the Chief of Cardiovascular Medicine, Director of the Sarver Heart Center and Co-Director of the Clinical Translational Sciences Graduate Program for the University of Arizona Health Sciences.

Researchers at Washington University School of Medicine in St. Louis have received a $6 million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) to harness new understandings of the immune system to develop innovative therapies for heart failure and the prevention of organ rejection following heart transplantation.

Tricuspid Regurgitation – Setting Standards for Diagnosis, Repair & Replacement. The Valve Team at Washington University School of Medicine is among the first in theworld to use a transfemoral transcatheter device for the treatment of severe tricuspidregurgitation (TR).

A study in mice — led by researchers at Washington University School of Medicine in St. Louis — shows that a new class of compounds the scientists developed can improve multiple aspects of metabolic syndrome. An increasingly common group of conditions that often occur together, metabolic syndrome includes type 2 diabetes, high cholesterol, fat buildup in the liver, and excess body fat, especially around the waist. This syndrome often leads to cardiovascular disease, the leading cause of death worldwide.